Clinical Trial Update: A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

View source ↗

Summary

A completed non-interventional study in Korea assessing lenalidomide (REVLIMID) for IPSS low- or intermediate-1-risk myelodysplastic syndromes with deletion 5q …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Myelodysplastic Syndromes

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndromes, Lymphoma, Mantle-Cell | Status: COMPLETED